Phaseline

Companies › AVVA Pharmaceuticals

AVVA Pharmaceuticals: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Infectious disease.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Clotrimazole
Cytochrome P450 51 inhibitor
ERGOSTEROLPhase 2Candidal Vulvovaginitis (ICD-10 Code: B37.3)–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06835361ClotrimazolePhase 2Candidal Vulvovaginitis (ICD-10 Code: B37.3)Infectious diseaseSep 2025

Targets

ERGOSTEROL (1)

Companies with the same targets

–

Companies built like this

Vasomune Therapeutics Altesa Biosciences Eagle Pharmaceuticals Code Pharma Peptilogics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.